A Study to Investigate the Safety, Tolerability, Immunogenicity, and Pharmacodynamics of VXX-401 Compared With Placebo in Adult Participants - Trial NCT05762276
Access comprehensive clinical trial information for NCT05762276 through Pure Global AI's free database. This Phase 1 trial is sponsored by Vaxxinity, Inc. and is currently Recruiting. The study focuses on Hypercholesterolemia. Target enrollment is 48 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Vaxxinity, Inc.
Timeline & Enrollment
Phase 1
Mar 07, 2023
Apr 03, 2024
Primary Outcome
Frequency of adverse events,Immunogenicity,Immunogenicity
Summary
This first-in-human (FIH) study of VXX-401, an anti-PCSK9 peptide-based immunotherapeutic
 candidate, is designed to assess the safety, tolerability, immunogenicity, and
 pharmacodynamics (PD) of VXX-401 and to determine an optimal dose regimen for LDL-C lowering
 in subsequent clinical trials.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05762276
Non-Device Trial